Crescent Biopharma, Inc.
CBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $20 | $12 | $0 | $0 |
| G&A Expenses | $6 | $9 | $2 | $5 |
| SG&A Expenses | $6 | $9 | $2 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $2 |
| Operating Expenses | $26 | $21 | $2 | $7 |
| Operating Income | -$26 | -$21 | -$2 | -$7 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | -$1 | $0 | $0 |
| Pre-Tax Income | -$25 | -$22 | -$2 | -$7 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$25 | -$22 | -$2 | -$7 |
| % Margin | – | – | – | – |
| EPS | -1,266.44 | -0.56 | -0.036 | -0.11 |
| % Growth | -226,050% | -1,442.7% | 67% | – |
| EPS Diluted | -1,266.44 | -0.56 | -0.036 | -0.11 |
| Weighted Avg Shares Out | 165 | 39 | 65 | 64 |
| Weighted Avg Shares Out Dil | 165 | 39 | 65 | 64 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$25 | -$21 | -$2 | -$5 |
| % Margin | – | – | – | – |